Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement

• Published in: PharmacoEconomics 2023-02, Vol.41 (2), p.175-186
• Main Authors: Gye, Amy, Goodall, Stephen, De Abreu Lourenco, Richard
• Format: Article
• Language: English
• Subjects: Acute lymphocytic leukemia; Antibodies, Bispecific - economics; Australia; Care and treatment; Child; Children; Cost benefit analysis; Cost-Effectiveness Analysis; Evaluation; Health Administration; Health aspects; Health Economics; Humans; Immunotherapy - economics; Medicine; Medicine & Public Health; Original; Original Research Article; Patient outcomes; Pharmacoeconomics and Health Outcomes; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Public Health; Quality of Life Research; Quality-Adjusted Life Years; Receptors, Antigen, T-Cell; T cells; Young Adult; Young adults
• ISSN: 1170-7690; 1179-2027
• DOI: 10.1007/s40273-022-01188-w

Objective This research assesses the impact of an outcome-based payment arrangement (OBA) linking complete remission (CR) to survival as a means of maintaining cost-effectiveness for a chimeric antigen receptor T cell (CAR-T) therapy in young patients with acute lymphoblastic leukemia (ALL). Methods A partitioned survival model (PSM) was used to model the cost-effectiveness of tisagenlecleucel versus blinatumomab in ALL from the Australian healthcare system perspective. A decision tree modeled different OBAs by funneling patients into a series of PSMs based on response. Outcomes were informed by individual patient data, while costs followed Australian treatment practices. Costs and quality-adjusted life years (QALYs) were combined to calculate a single incremental cost-effectiveness ratio (ICER), reported in US dollars (2022) at a discount rate of 5% on costs and outcomes. Results For the base case, incremental costs and benefit were $379,595 and 4.27 QALYs, giving an ICER of $88,979. The ICER was most sensitive to discount rate ($57,660–$75,081), “cure point” ($62,718–$116,206) and extrapolation method ($76,018–$94,049). OBAs had a modest effect on the ICER when response rates varied. A responder-only payment was the most effective arrangement for maintaining the ICER ($88,249–$89,434), although this option was associated with the greatest financial uncertainty. A split payment arrangement (payment on infusion followed by payment on response) reduced variability in the ICER ($82,650–$99,154) compared with a single, upfront payment ($77,599–$107,273). Conclusion OBAs had a modest impact on reducing cost-effectiveness uncertainty. The value of OBAs should be weighed against the additional resources needed to administer such arrangements, and importantly overall cost to government.